Drug Profile

PC 111

Alternative Names: PC-111

Latest Information Update: 28 Jul 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator PinCell
Class Anti-inflammatories; Monoclonal antibodies; Skin disorder therapies
Mechanism of Action Fas ligand protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Pemphigus
New Molecular Entity Yes
Available For Licensing Yes - Pemphigus

Highest Development Phases

Preclinical Stevens-Johnson syndrome
No development reported Pemphigus

Most Recent Events

28 Jul 2026 No recent reports of development identified for preclinical development in Pemphigus in Italy (Parenteral)
29 Jul 2025 Pharmacodynamics data from a preclinical studies in Stevens Johnson syndrome released by Scinai Immunotherapeutics
27 Mar 2025 PC-111 exclusively licensed to subsidiary of Scinai worldwide

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com